ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Source: Newsfilter
Special Meeting Announcement: ACELYRIN, Inc. has scheduled a special meeting for stockholders on May 13, 2025, to vote on the proposed merger with Alumis Inc., urging stockholders to vote in favor of the transaction to maximize their investment value.
Board's Confidence in Merger: The ACELYRIN Board unanimously recommends the merger, highlighting that it will create a leading clinical-stage immunology company and provide significant potential upside for stockholders, who would retain approximately 48% ownership in the combined entity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
